JAVELIN Bladder Medley results posted; Merck files separate MK-2010 trial across six tumor types
EMD Serono's avelumab maintenance study in bladder cancer reports results, while Merck Sharp & Dohme registers a new Phase 2 study for its immunotherapy candidate MK-2010.
Two unrelated sponsor records updated this period, one with new trial results and one newly registered.
- "JAVELIN Bladder Medley" (NCT05327530), a Phase II umbrella study testing avelumab combinations as maintenance therapy in locally advanced or metastatic urothelial carcinoma, is listed as active not recruiting with results first posted on 2026-09-01. The study enrolled 256 participants (actual)1 and reached primary completion on 2025-06-20 (actual). The design compares avelumab alone against combinations with sacituzumab govitecan, M6223, and NKTR-255, with Merck KGaA, Darmstadt, Germany, Gilead Sciences, and Nektar Therapeutics listed as collaborators1.
- MK-2010-002 (NCT07793942), a Phase 2 study of MK-2010 as monotherapy and in combination with chemotherapy regimens or belzutifan in advanced solid tumors, is sponsored by Merck Sharp & Dohme LLC2 and listed as not yet recruiting2, with a first posted date of 2026-08-312. The study plans to enroll 480 participants (estimated)2 across seven arms, including comparisons against pembrolizumab plus FOLFOX, and its primary outcomes track the number of participants with adverse events, assessed up to approximately 24 months2.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.